Chemotherapy in osteosarcoma

Sæter, Gunnar; Wiebe, Thomas; Wıklund, Tom; Wahlqvist, Yngve; Engström, Karl Gunnar; Forestier, Erik; Holmström, Teddy; Stenwig, Anna E.; Willén, Helena; Brosjö, Otte; Follerås, Gunnar; Alvegård, Thor; Strander, Hans

doi:10.1080/17453674.1999.11744828

Cited by 34 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Factors linked with chemotherapy-induced liver toxicity comprised of increased chemotherapy quantities, elevated plasma methotrexate levels, and a more gradual pre-hydration velocity [31]. The quality of life of patients undergoing treatment for osteosarcoma was assessed in a prospective international study, which found that the disease itself and the treatment applied to the patients may negatively impact the patients quality of life [5]. Another study evaluated the quality of life of individuals with cancer undergoing chemotherapy was reported symptoms such as nausea, vomiting, reduction in appetite, fatigue, constipation, and diarrhea might influence the patients quality of life [32].…”

Section: Discussionmentioning

confidence: 99%

“…Chemotherapy was implemented as a therapeutic approach for osteosarcoma during the early 1970s. At first, osteosarcoma displayed resistance towards chemotherapy; however, subsequent findings on the effectiveness of adriamycin and high-dose methotrexate agents brought favorable outcomes among osteosarcoma patients [3][4][5]. Subsequently, additional therapeutic agents such as cisplatin, ifosfamide, and cyclophosphamide have demonstrated efficacy in the eradication or induction of regression in neoplastic growths [3].…”

Section: Introductionmentioning

confidence: 99%

“…Combination therapies utilizing these agents have markedly enhanced the overall Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis survival rate of individuals afflicted with osteosarcoma [4]. Nevertheless, in spite of these advancements, there has been a lack of progress in the general prognosis for patients diagnosed with osteosarcoma over the last four decades [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Ismail,

Wiratnaya,

Raditya

2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Several studies of multi-drug regimens for osteosarcoma have shown different efficacies and are still controversial. Meanwhile, chemotherapy options have remained largely unchanged over a couple of decades. This study is designed to ascertain the outcome and safety of Methotrexate, Doxorubicin, and Cisplatin regimen for chemotherapy in osteosarcoma patients through the utilization of meta-analysis. Methods: We interrogated trials that compared the MAP regimen with other regimens as chemotherapy for osteosarcoma from several databases encompassing PubMed, Science Direct, and grey literature (Google Scholar) until December 2022. The analyzed outcomes including Event-Free Survival (EFS), Overall Survival (OS), Tumor Necrosis (TN) rate, and Adverse Event (AE) were then analyzed using RevMan 5.4 software in fixed or random effect models. Results: Our meta-analysis comprised 8 prospective articles that evaluated a cumulative number of 2920 OS patients. The analysis results indicated no meaningful difference in 5-year EFS (OR=0.99, 95% CI=0.77-1.27, [P = 0.91]) and neoadjuvant chemotherapy response (TN) (OR=0.76, 95% CI=0.49-1.17, [P = 0.22]) between the MAP and control groups. Furthermore, 5-year OS analysis revealed a significant association in the control group (OR=0.82, 95% CI=0.68-0.99, [P = 0.04]). However, the control group was associated with statistically meaningful AE compared to the MAP group, particularly in thrombocytopenia (OR=0.46, 95% CI=0.23-0.90, [P = 0.02]) and fever (OR=0.34, 95% CI=0.26-0.46, [P < 0.00001]). Conclusion: The present meta-analysis showed that the MAP regimen remains preferable in treating osteosarcoma patients despite no significant outcome compared to the other regimens considering the less frequent AE in the MAP regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Ismail,

Wiratnaya,

Raditya

2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…( 4) Use alcohol to wipe the plate electrode of IPGphor, wait for the alcohol evaporates completely. (5) Remove the rubber strips freeze-dried at -20 ℃ in the refrigerator, balance for 10 minutes at the room temperature. (6) Parallele the rubber strip grooves on flat electrode of IPGphor, put the sample evenly into the strip groove, balance rubber strip in room temperature, use tweezers to gently remove prefabricated dry film strip.…”

Section: A General Materialsmentioning

confidence: 99%

“…As one of the most common adolescent malignancies [1][2]， osteosarcoma not only has a high degree of malignancy, but often early onsets lung metastasis [3], so it was used as the research object. Accompanied by a series of drugs applied to clinical treating, 5-year survival rate of patients with osteosarcoma has been greatly improved by high-dose chemotherapy [4]; through the rational, active chemotherapy, the limbs of approximately 80% of patients with osteosarcoma can be preserved [5][6][7]. The cure rate reached 50%-80% from less than 20% by surgery alone [8].…”

Section: Introductionmentioning

confidence: 99%

Detection of Differentially Expressed Proteins of Capsulation-Resistant and Sensitive Osteosarcoma Tissue

Zhang

2013

AMR

View full text Add to dashboard Cite

The tissue samples of cisplatin-resistant and sensitive patients with osteosarcoma were obtained through chemosensitivity testing before. The typical one of cisplatin-resistant and sensitive osteosarcoma tissue samples were analyzed by two-dimensional electrophoresis and the relevant differentially expressed proteins were obtained. The sequences of differentially expressed proteins were obtained through the analysis of mass spectrometry technology to be identified comparing with protein databases. It is concluded that there are differentially expressed proteins in tissue of cisplatin-resistant and sensitive osteosarcoma.

show abstract

Osteosarcoma

Davis¹,

Wunder²,

Bell³

2014

TNM Online

View full text Add to dashboard Cite

Primary bone tumors are rare with an incidence of 2 to 3 per million, and of these, high‐grade osteosarcoma is the most common, representing 35% of all bone sarcomas. The typical patient diagnosed with osteosarcoma is male, between the ages of 10 and 20 years, and complains of pain for one to three months. The tumor is most commonly at the metaphysis of a long bone, with a predilection to the knee region. Dramatic improvements in disease‐free (DFS) and overall survival (OS) were demonstrated with the advent of doxorubicin and methotrexate chemotherapy regimes. The current standard of treatment for the patient with osteosarcoma is chemotherapy and resection of the primary tumor, most commonly preserving the limb. Despite the advances in radiological imaging, chemotherapy and surgery, 40 to 50% of patients will develop distant metastases and die of their disease. This chapter discusses the prognostic factors of disease outcome for osteosarcoma patients, specifically disease‐ or tumor‐related factors, host‐related factors, and environment‐ or treatment‐related factors.

show abstract

Chemotherapy in osteosarcoma

Cited by 34 publications

References 23 publications

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis

Detection of Differentially Expressed Proteins of Capsulation-Resistant and Sensitive Osteosarcoma Tissue

Osteosarcoma

Contact Info

Product

Resources

About